Table 2.

Angiogenesis inhibitors approved by FDA.

Drug	Target Molecule	Approved Disease
Bevacizumab	Anti-VEGF monoclonal antibody	mCRC, NSCLC, mRCC, ovarian cancer, malignant glioma, advanced cervical cancer, fallopian tube cancer, primary peritoneal cancer
Ramucirumab	Anti-VEGFR2 monoclonal antibody	Advanced gastric or gastroesophageal junction adenocarcinoma, NSCLC, advanced colorectal cancer
Ziv-aflibercept	Soluble decoy of VEGFR	Metastatic colorectal cancer
Sunitinib	TKI: VEGFR, PDGFR, FLT3, KIT	RCC, Gastrointestinal stromal tumor, pancreatic neuroendocrine tumor
Sorafenib	TKI: VEGFR, PDGFR, FLT3, KIT, Raf	RCC, unresectable hepatocellular carcinoma, metastatic or recurrent thyroid carcinoma
Axitinib	TKI: VEGFR, PDGFR, KIT	Advanced RCC
Pazopanib	Multiple targeted receptor TKI	RCC, Advanced soft tissue sarcoma
Vandetanib	TKI: VEGFR, EGFR, RET	Unresectable or metastatic medullary thyroid cancer